Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. As a biotechnology company developing and commercializing therapies for gastrointestinal (GI) and rare diseases, Ironwood uses these filings to report on its financial condition, collaboration revenues from LINZESS® (linaclotide), progress of its apraglutide program, capital structure and risk factors.
In its annual reports on Form 10-K, Ironwood presents audited financial statements, management’s discussion and analysis of results, details on its GI and rare disease portfolio, and information about collaborations with partners such as AbbVie, Astellas and AstraZeneca. These filings also describe material weaknesses in internal control over financial reporting identified as of December 31, 2024, and the company’s efforts to address them.
Quarterly reports on Form 10-Q update investors on interim financial performance, including collaboration revenue tied to LINZESS U.S. net sales, research and development expenses related to apraglutide and other programs, restructuring charges, interest expense on convertible senior notes and revolving credit facilities, and non-GAAP measures such as adjusted EBITDA and non-GAAP net income or loss.
Current reports on Form 8-K provide timely disclosure of specific events. For Ironwood, 8-K filings in 2025 have covered topics such as Nasdaq notifications about bid price and filing timeliness, the company’s receipt of a Maximum Fair Price determination for LINZESS under the Inflation Reduction Act, changes in the independent registered public accounting firm, director resignations, and the public release of quarterly earnings press releases.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, such as shifts in financial guidance, updates on the apraglutide regulatory path, or changes in collaboration economics. Users can quickly identify information related to annual reports (10-K), quarterly reports (10-Q) and current reports (8-K), and can review disclosures that affect listing status, internal controls, and major GI and rare disease programs.
This page also helps investors monitor governance and compliance developments, including responses to Nasdaq listing rules and auditor changes, alongside the financial and operational data that shape the IRWD investment profile.
Ironwood Pharmaceuticals insider sale was a routine, non-discretionary sell-to-cover tied to restricted stock unit vesting. Chief Commercial Officer Tammi L. Gaskins sold 1,316 shares of Class A common stock on 08/11/2025 at a reported price of $0.84 per share to satisfy tax withholding obligations. After the transaction the reporting person beneficially owned 241,280 shares directly.
The filing states the sale occurred automatically to cover tax withholding and "does not represent a discretionary trade by the Reporting Person." This indicates the transaction was an administrative tax-related sale rather than a voluntary disposition of shares.
John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals (IRWD), reported an automatic sale of 7,754 shares of Class A common stock on 08/11/2025 at $0.84 per share to satisfy tax withholding obligations arising from vested restricted stock units. Following the sale he beneficially owned 400,378 shares directly. The filing specifies this was a routine sell-to-cover tied to RSU vesting and notes no derivative transactions were reported.
Gregory S. Martini, Chief Financial Officer of Ironwood Pharmaceuticals (IRWD), sold 1,265 shares of Class A common stock on 08/11/2025 at $0.84 per share and retained 182,545 shares of direct beneficial ownership.
The Form 4 states the sale was an automatic "sell-to-cover" to satisfy tax withholding obligations arising from the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
Ronald Silver, identified as an officer (Principal Accounting Officer) of Ironwood Pharmaceuticals (IRWD), reported a sale of 2,846 Class A common shares on 08/11/2025 at $0.84 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. The filing states the sale was an automatic sell-to-cover transaction to fund withholding and was not a discretionary trade.
After the reported transaction the reporting person beneficially owned 276,809 shares, held directly. The Form 4 lists no derivative transactions and includes an explanation that the disposition was solely to cover taxes related to RSU vesting.
Barclays PLC reports beneficial ownership of 11,133,857 shares of Ironwood Pharmaceuticals common stock, representing 6.88% of the class. The statement shows Barclays has sole voting and dispositive power over these shares and indicates the securities are held in the ordinary course of business and were not acquired to change or influence control. The filing names Barclays Bank PLC, Barclays Capital Inc. and Barclays Capital Securities Ltd. as relevant subsidiaries associated with the reported holdings.
Ironwood Pharmaceuticals reported a profitable quarter but a loss for the first half of 2025. For the three months ended June 30, 2025 the company recorded $23.6 million of net income (basic EPS $0.15), driven by collaborative arrangements revenue of $85.2 million and reduced operating costs. For the six months ended June 30, 2025, revenue from collaborative arrangements was $126.4 million versus $169.3 million a year earlier, and the company recorded a $13.8 million net loss for the period.
The balance sheet shows $92.9 million of cash and cash equivalents and accounts receivable of $86.2 million, largely due from AbbVie. Current liabilities increased sharply to $232.5 million primarily because the $200.0 million 2026 Convertible Notes are presented, in part, as a current obligation (net carrying amount $199.3 million) and these notes mature on June 15, 2026. Management states available liquidity and borrowing capacity are sufficient to meet operations for at least the next 12 months.
This Form 144 notifies a proposed sale of 8,281 shares of Ironwood Pharmaceuticals, Inc. Class A common stock with an aggregate market value of $7,287.28. The sale is listed to occur through E Trade Securities LLC on the Nasdaq exchange on 08/11/2025. The securities were originally acquired as a Restricted Stock Unit award under the issuer's 2019 Equity Incentive Plan on 08/02/2021, with 19,973 units shown as acquired on that date.
The filing reports 161,819,848 shares outstanding, and indicates no securities sold in the past three months by the person for whose account the sale is filed. The notice includes the filer's representation that they do not know of any undisclosed material adverse information regarding the issuer.
Ironwood Pharmaceuticals filed a Form 144 reporting a proposed sale of 1,351 shares of Class A common stock on Nasdaq, with an aggregate market value of $1,188.88. The sale is listed with an approximate sale date of 08/11/2025. The filer acquired 4,000 shares as a Restricted Stock Unit award on 08/16/2023, and no securities of the issuer were reported sold by the filer in the past three months.
The filing includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer. The shares to be sold amount to approximately 0.000835% of the 161,819,848 shares outstanding, indicating a very small proposed disposition relative to the company’s market capitalization.
Ironwood Pharmaceuticals Form 144 reports that Tammi Gaskins proposes to sell 1,406 shares of Class A common stock on 08/11/2025 through E Trade (Nasdaq), with an aggregate market value of $1,237.28. The filing states these shares were acquired as 4,000 restricted stock units granted on 08/16/2023.
The notice also discloses a prior sale of 2,563 shares on 05/16/2025 for gross proceeds of $1,486.54. The filer affirms they do not possess undisclosed material adverse information.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
